ROSALINDA ALAY: Open Payments
NPI 1437537289 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,412 in 151 payments from 24 companies in 2025. Trend: 2023 $3,149 · 2024 $2,143 · 2025 $3,412
Food & beverage: $3,309Education: $103
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $586 |
| GlaxoSmithKline, LLC. | 24 | $346 |
| United Therapeutics Corporation | 6 | $246 |
| Regeneron Healthcare Solutions, Inc. | 10 | $217 |
| Verona Pharma, Inc. | 18 | $205 |
| Mallinckrodt Hospital Products Inc. | 7 | $197 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $188 |
| Viatris Specialty LLC | 10 | $186 |
| Grifols USA, LLC | 2 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $173 |
Products named: DUPIXENT, FASENRA, Ohtuvayre, ACTHAR, OFEV, YUPELRI, BREZTRI, Prolastin-C Liquid.
Industry payments across FL — which companies pay providers there.
